Latest developments and achievements

News

Stay informed about the latest developments and achievements from TRICALS. Here we will report about our progress and the accomplishments of our large scale collaboration. Browse and read the latest news to stay updated along our journey to find a treatment for ALS.

Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug…
Stay in [u]touch[/u]

Stay in touch

Would you like to keep up to date with the latest news from TRICALS? Click on the button below to subscribe to our newsletter

Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study,…
Amylyx: no effect after analyzing phase 3 study
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study.…
Tofersen receives positive opinion from CHMP (EMA)
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European…
Results ADORE study: no effect of medication
Results ADORE study: no effect of medication
The pharmaceutical company Ferrer has announced their first results of the ADORE…
34th International Symposium on ALS/MND
34th International Symposium on ALS/MND
From 6 to 8 December 2023, more than 1300 people from all…
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request takes action for ALS Foundation Netherlands
3FM Serious Request is taking action for the ALS Foundation Netherlands during…
Over 200 patients participate in Lighthouse II study worldwide
Over 200 patients participate in Lighthouse II study worldwide
The Lighthouse II study is a phase 3 clinical trial that compares…
ENCALS consensus statement on NurOwn
ENCALS consensus statement on NurOwn
Background Given the interest around the use of stem cells in ALS,…
Story behind the participant: Peter Ambühl
Story behind the participant: Peter Ambühl
Many clinical trials are looking for participants. In this new interview series,…